Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer-a problem still to be solved

被引:6
|
作者
Schmidt, M. [1 ]
Untch, M. [2 ]
机构
[1] Univ Hosp, Dept Obstet & Gynaecol, Mainz, Germany
[2] Univ Gottingen, Dept Obstet & Gynaecol, Multidisciplinary Breast Canc Ctr, Helios Klinikum Berlin Buch,Acad Hosp, Berlin, Germany
关键词
WOMEN;
D O I
10.1093/annonc/mdt595
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This is a definite statement, however, we want to draw attention to the fact that this evidence is based on two clinical trials including also HER2-positive breast cancer patients. This inclusion of HER2-positive patients might alter the predictive value of RS in luminal HER2-negative breast cancer patients and we thus consider it important to discuss this issue publicly.
引用
收藏
页码:754 / 754
页数:1
相关论文
共 50 条
  • [21] A predictor model for pathological CR after neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer
    Fujiki, Yoshitaka
    Yamamoto, Yutaka
    Tomiguchi, Mai
    Sueta, Aiko
    Takeshita, Takashi
    Ibusuki, Mutsuko
    Iwase, Hirotaka
    CANCER SCIENCE, 2018, 109 : 654 - 654
  • [22] New Approaches to Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer
    Hamilton, Erika P.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (06) : 356 - 358
  • [23] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
    G. Hoste
    K. Punie
    H. Wildiers
    B. Beuselinck
    I. Lefever
    E. Van Nieuwenhuysen
    S. N. Han
    P. Berteloot
    N. Concin
    R. Salihi
    I. Vergote
    P. Neven
    Breast Cancer Research and Treatment, 2018, 171 : 131 - 141
  • [24] Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers
    Hilbers, Florentine S.
    Poncet, Coralie
    Tryfonidis, Konstantinos
    Viale, Giuseppe
    Delaloge, Suzette
    Pierga, Jean-Yves
    Brain, Etienne G. C.
    Rubio, Isabel T.
    Thompson, Alastair M.
    Rutgers, Emiel J. T.
    Piccart, Martine J.
    van 't Veer, Laura J.
    Cardoso, Fatima
    NPJ BREAST CANCER, 2024, 10 (01)
  • [25] Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer
    Loo, Claudette E.
    Rigter, Lisanne S.
    Pengel, Kenneth E.
    Wesseling, Jelle
    Rodenhuis, Sjoerd
    Peeters, Marie-Jeanne T. F. D. Vrancken
    Sikorska, Karolina
    Gilhuijs, Kenneth G. A.
    BREAST CANCER RESEARCH, 2016, 18
  • [26] Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer
    Claudette E. Loo
    Lisanne S. Rigter
    Kenneth E. Pengel
    Jelle Wesseling
    Sjoerd Rodenhuis
    Marie-Jeanne T. F. D. Vrancken Peeters
    Karolina Sikorska
    Kenneth G. A. Gilhuijs
    Breast Cancer Research, 18
  • [27] Mechanisms of primary AI resistance in ER-positive HER2-negative breast cancer.
    Miura, Daishu
    Iwatani, Tsuguo
    Kawabata, Hidetaka
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer
    Ueno, Takayuki
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [29] 20-year tamoxifen benefit in ER-positive/HER2-negative breast cancer patients in randomized clinical trials
    Dar, H. A.
    Johansson, A.
    Nordenskjold, A.
    Yau, C.
    Benz, C.
    Essermann, L.
    Rodriguez-Wallberg, K. A.
    Nordenskjold, B. A.
    Perez-Tenorio, G.
    Stal, O.
    Fornander, T.
    Lindstrom, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S153 - S154
  • [30] Identification of key differentially expressed genes between ER-positive/HER2-negative breast cancer and ER-negative/HER2-negative breast cancer using integrated bioinformatics analysis
    Gan, Siyuan
    Dai, Haixia
    Li, Rujia
    Liu, Wang
    Ye, Ruifang
    Ha, Yanping
    Di, Xiaoqing
    Hu, Wenhua
    Zhang, Zhi
    Sun, Yanqin
    GLAND SURGERY, 2020, 9 (03) : 661 - 675